Xconomy: Gossamer Bio Adds $276M in Second Biotech "Unicorn" IPO of 2019
Phase 2 deja vu for gossamer after ulcerative colitis med flops
From Launch To IPO In 13 Months: Gossamer Bio's CEO Says She's Running The Company Of Her Dreams
Gossamer Bio Company Profile: Stock Performance & Earnings | PitchBook
Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation
Taking A Gander At Gossamer Bio (NASDAQ:GOSS) | Seeking Alpha
Analyst Rating: Will Gossamer Bio Inc (GOSS) Stock Lead the Market?
Platform for Success: Gossamer Bio's Quest to Build a Sustainable Company & Culture - WuXi XPress: for WuXi news and R&D insights
Xconomy: Gossamer Bio Files for IPO at End of Year in Which It Raised $330M
Work at Gossamer - Gossamer Bio
Locations - Gossamer Bio
Gossamer Bio Inc tumbles as hypertension drug underperforms rival product in Phase 2 trial
OrbiMed taps former Moderna CMO and Gossamer Bio co-founder - Drug Discovery and Development
:quality(70)/arc-anglerfish-arc2-prod-tronc.s3.amazonaws.com/public/3OZMHOPBB5GENE3O55BB3HL2YU.jpg "San Diego's Gossamer Bio raises $230 million for immune system drugs – Chicago Tribune")
San Diego's Gossamer Bio raises $230 million for immune system drugs – Chicago Tribune
Gossamer shares plummet after latest DP2 drug setback
Secretive Biotech Startup Gossamer Bio Bags $230 Million in Series B Funding - Healthcare Weekly
Taking A Gander At Gossamer Bio (NASDAQ:GOSS) | Seeking Alpha
Gossamer Bio (@GossamerBio) / Twitter
Why Gossamer Bio Stock Is Tumbling Today | The Motley Fool
Gossamer Bio, Inc. (GOSS) Company Profile & Overview - Stock Analysis
What 9 Analyst Ratings Have To Say About Gossamer Bio | Markets Insider
Gossamer unveils new pipeline plans a year after lead program fizzled out in phase 2 | Fierce Biotech
Gossamer Bio (@GossamerBio) / Twitter
